PMID- 33121338
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211030
IS  - 1555-8576 (Electronic)
IS  - 1538-4047 (Print)
IS  - 1538-4047 (Linking)
VI  - 21
IP  - 11
DP  - 2020 Nov 1
TI  - Rituximab-induced acute thrombocytopenia in patients with splenomegaly B Cell 
      lymphoma: an underdiagnosed but severe complication.
PG  - 1060-1066
LID - 10.1080/15384047.2020.1832017 [doi]
AB  - Rituximab is popularly used in the treatment of B-cell lymphomas that bear CD20 
      antigen. Most of the adverse events (AEs) induced by rituximab are 
      infusion-related symptoms. However, rituximab-induced acute thrombocytopenia 
      (RIAT), which often develops within the 1-3 days after rituximab administration, 
      is relatively unusual, severe, and usually self-recovering. Until now, most of 
      the reports about RIAT were described as case reports and RIAT often occurred in 
      patients with mantle cell lymphoma (MCL). Here, we report two patients who 
      developed severe RIAT, one patient had a refractory and relapsed follicular 
      lymphoma (FL), and the other patient was newly diagnosed with splenic marginal 
      zone lymphoma (SMZL). RIAT is a rare, under-diagnosed but serious adverse event 
      that should arouse attention to clinicians, and routine blood count monitoring 
      should be considered after the administration of rituximab, especially for 
      high-risk lymphoma patients or patient with splenomegaly.
FAU - Jiang, Yujie
AU  - Jiang Y
AUID- ORCID: 0000-0003-2199-238X
AD  - Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong 
      University , Jinan, China.
FAU - Song, Jiqing
AU  - Song J
AD  - Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong 
      University , Jinan, China.
FAU - Wang, Na
AU  - Wang N
AD  - Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong 
      University , Jinan, China.
FAU - Yuan, Dai
AU  - Yuan D
AD  - Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong 
      University , Jinan, China.
FAU - Feng, Lili
AU  - Feng L
AD  - Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong 
      University , Jinan, China.
FAU - Qu, Huiting
AU  - Qu H
AD  - Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong 
      University , Jinan, China.
FAU - Fan, Juan
AU  - Fan J
AD  - Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong 
      University , Jinan, China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201029
PL  - United States
TA  - Cancer Biol Ther
JT  - Cancer biology & therapy
JID - 101137842
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Female
MH  - Humans
MH  - Lymphoma, B-Cell/*complications/*drug therapy
MH  - Middle Aged
MH  - Rituximab/*adverse effects
MH  - Splenomegaly/*complications/*drug therapy
MH  - Thrombocytopenia/*chemically induced
PMC - PMC7678941
OTO - NOTNLM
OT  - B cell lymphoma
OT  - Rituximab
OT  - Splenomegaly
OT  - Thrombocytopenia
COIS- The authors declare no competing  fi nancial interests for this study.
EDAT- 2020/10/31 06:00
MHDA- 2021/10/21 06:00
PMCR- 2021/10/29
CRDT- 2020/10/30 05:31
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2020/10/30 05:31 [entrez]
PHST- 2021/10/29 00:00 [pmc-release]
AID - 1832017 [pii]
AID - 10.1080/15384047.2020.1832017 [doi]
PST - ppublish
SO  - Cancer Biol Ther. 2020 Nov 1;21(11):1060-1066. doi: 
      10.1080/15384047.2020.1832017. Epub 2020 Oct 29.